OssDsign: Strengthening the balance sheet to take on next steps
Research Update
2021-04-06
07:20
Redeye returns with a review of OssDsign following its announced rights issue and recently presented strategy update – ASCENT25. We are encouraged by its intensified focus on its neurosurgery product portfolio and its new, though adjacent, vertical in spine, strengthening our already favourable view on its longer-term prospects.
OB
Oscar Bergman
Disclosures and disclaimers